Results The Hb≥ 110 g/l was registered in 37 (53.6%) patients. Patients with Hb≥ 110 g/l
were characterized by significantly higher serum levels of albumin, cholesterol, and iron …

Purpose To evaluate the frequencies of angiotensin-converting enzyme gene‎ polymorphism
in‎ Iraqi hemodialysis patients and to examine the association‎ between this polymorphism …

Background: Anemia could be a commonly analyzed complication in patients enduring from
chronic kidney infection. Erythropoietin (EPO) stimulating agents (ESAs) and iron …

Background: Angiotensin-converting enzyme inhibitors (ACEis) improve survival; however,
their effect on erythropoiesis remains a matter of debate in this population. Since …

Purpose This is the first cross-sectional study studying the changes in haematological
indicators of the response to recombinant human erythropoietin (rHuEPO) therapy in chronic …

Background Hyporesponse to erythropoietin is a common problem seen in around 5-10% of
patients. Recently the focus from these remediable factors has been shifted to the non …

Angiotensin-converting enzyme (ACE)-gene polymorphism is a possible predisposing factor
of erythropoietin response under hypoxic conditions. However, it is not completely clear …

Chronic kidney disease (CKD) is characterized by elevated levels of pro-inflammatory
cytokines. Interleukin-6 (IL-6) is a pleiotropic and pro-inflammatory cytokine involved in …

Genetic polymorphisms may be linked to inter-individual differences in erythropoietin (EPO)
resistance. We investigated the-511C/T polymorphism of the IL-1B gene and the I/D …

Background The correction of anemia by recombinant human erythropoietin (rHuEPO)
improves quality of life and prolongs life in end-stage renal failure. rHuEPO requirements for …